UFP Technologies has delivered earnings beats in all four consecutive recent quarters with an average surprise of 9.4%, reflecting improving execution in medical devices, though high short interest of 20% and elevated put/call ratio of 2.67 signal meaningful bearish positioning that must be worked through.
Thesis pillars
- Analyst Upside Versus Risk Reward↓Deteriorating
- Perfect Four Quarter Beat Streak→Stable
- Strong Momentum With Macd Signal↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 27, 2026· older than 90 days
UFP Technologies, Inc. (UFPT) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $329.82, but acceptable to hold if already in. Reasons: Concentration risk — Customer: top ten customers (68.8%); Analyst target reached - limited upside remaining.
UFP Technologies is a contract development and manufacturing organization producing single-use and single-patient medical devices and components for minimally invasive surgery, infection prevention, wound care, and orthopedics. The company generates revenue by manufacturing... Read more
Hold if already holding. Not a fresh buy at $329.82, but acceptable to hold if already in. Reasons: Concentration risk — Customer: top ten customers (68.8%); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.
Passes 4/7 gates (positive momentum, earnings proximity 110d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About UFP Technologies, Inc.
About UFP Technologies, Inc.
UFP Technologies operates nineteen ISO 13485-certified manufacturing sites, thirteen of them FDA-registered, producing single-use and single-patient medical devices for surgical, wound-care, and orthopedic applications. Two customers, Intuitive Surgical SARL and Stryker, accounted for approximately 24.3% and 21.5% of net sales in 2025, respectively, while the top ten customers together represented about 68.8% of net sales. The company also runs manufacturing operations in the Dominican Republic.
UFP Technologies earns revenue as a contract developer and manufacturer, converting foam, plastics, and other specialty materials into custom-engineered components through cutting, molding, thermoforming, and welding processes for medical device customers. The company sells principally through a direct sales force, with commercial leaders and engineers collaborating with customers to develop application-specific solutions across minimally invasive surgery, infection prevention, wound care, and orthopedic implants. Raw materials such as cross-linked foam, technical polyurethane foam, and thermoplastic urethane come from a limited number of suppliers, though the company describes its supplier relationships as good. Competition comes primarily from smaller independent regional manufacturers rather than large national converters, and some customers have brought manufacturing in-house or could do so, a dynamic the filing flags as a competitive risk. Research and development is described as an integral part of the company's ongoing cost structure rather than a standalone profit center.
Show full overview
UFP Technologies' customer base is concentrated enough that a single lost account could move results: Intuitive Surgical SARL and Stryker together represented about 45.8% of 2025 net sales, and one customer held 32.1% of gross accounts receivable at year-end. The company also disclosed a material information-technology security incident detected on February 14, 2026, in which data were exfiltrated from systems supporting billing and shipping-label functions, with the investigation into affected personal information still ongoing. Combined with reliance on a limited number of suppliers for cross-linked and technical polyurethane foam and TPU, and manufacturing operations near civil unrest in Haiti that could disrupt Dominican Republic facilities, the filing points to concentrated commercial and operational dependencies rather than commodity-style diversification.
See also: Healthcare · Medical Devices
From UFP Technologies, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 2, 2026Recent Developments — UFP Technologies, Inc.
Latest news
- NEWS UFP Technologies (UFPT) Stock Dropped, So What Is Driving Attention Today? - Simply Wall St — Simply Wall St Nov 2, 2026 negative
- NEWS Do UFP Technologies' (NASDAQ:UFPT) Earnings Warrant Your Attention? - Moomoo — Moomoo Oct 29, 2026 neutral
- NEWS UFPT Q3'26 Earnings: revenue estimate is 166.89M USD - TradingView — TradingView Oct 28, 2026 neutral
- NEWS UFP Technologies (UFPT) Expected to Release Quarterly Earnings on Monday - MarketBeat — MarketBeat Oct 26, 2026 neutral
- NEWS UFPT270115P00240000 Interactive Stock Chart | UFPT Jan 2027 240.000 put Stock - Yahoo Finance — Yahoo Finance Oct 26, 2026 neutral
Latest item Nov 2, 2026 · Generated 2026-11-05T11:44:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertop ten customers69%10-K Item 1A: 'Our top ten customers represented approximately 68.8%, 68.1%, and 59.3% of our total net sales in 2025, 2024, and 2023, respectively.'
- LOWCustomerIntuitive Surgical SARL24%10-K Item 1A: 'Two customers (Intuitive Surgical SARL and Stryker) comprised approximately 24.3% and 21.5%, respectively, of our net sales for the year ended December 31, 2025'
- LOWCustomerStryker22%10-K Item 1A: 'Two customers (Intuitive Surgical SARL and Stryker) comprised approximately 24.3% and 21.5%, respectively, of our net sales for the year ended December 31, 2025'
- MEDIUMSuppliercross-linked and technical polyurethane foam and TPU suppliers10-K Item 1: 'the Company relies upon a limited number of suppliers for cross-linked and technical polyurethane foams, and TPU'
Material Events(8-K, last 90d)
- 2026-06-10Item 5.02MEDIUMThe company appointed Ryan Stafford as General Counsel, SVP of Human Resources, and Secretary effective June 4, 2026, succeeding Christopher P. Litterio, who previously disclosed plans to retire after a transition period.SEC filing →
- 2026-05-26Item 5.02MEDIUMGeneral Counsel, Secretary, and SVP of Human Resources Christopher P. Litterio informed the company on May 19, 2026 that he plans to retire after a period of transition. No successor named in this filing.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $329.82, but acceptable to hold if already in. Reasons: Concentration risk — Customer: top ten customers (68.8%); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Analyst target $301.75 reached (−8.5%), stop $306.73 (−7.5%), A.R:R -0.6:1. Score 5.8/10, moderate confidence.
Analyst target $301.75 reached (−8.5% from $329.82); no take-profit level is published. Analyst target $301.75 reached (−8.5%), stop $306.73 (−7.5%), A.R:R -0.6:1. Stop-loss: $306.73.
Concentration risk — Customer: top ten customers (68.8%); Analyst target reached - limited upside remaining; Near 52-week high (3.6% away).
UFP Technologies, Inc. trades at a P/E of 33.7 (forward 27.8). TrendMatrix value score: 4.2/10. Verdict: Hold.
10 analysts rate UFPT, with a consensus score of 3.9/5. 2 analysts publish price targets averaging $355.
What does UFP Technologies, Inc. do?UFP Technologies is a contract development and manufacturing organization producing single-use and single-patient...
UFP Technologies is a contract development and manufacturing organization producing single-use and single-patient medical devices and components for minimally invasive surgery, infection prevention, wound care, and orthopedics. The company generates revenue by manufacturing custom-engineered products for medical device makers; its top ten customers represented approximately 68.8% of net sales in 2025, including Intuitive Surgical SARL and Stryker at 24.3% and 21.5%, respectively.